Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate CancerMatti Annala, Kim N., Gillian Vandekerkhove et al.|Cancer Discovery|2018Cited by 520
Treatment Outcomes and Tumor Loss of Heterozygosity in Germline DNA Repair–deficient Prostate CancerMatti Annala, Alexander W. Wyatt, Daniel Khalaf et al.|European Urology|2017Cited by 218
Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate CancerGillian Vandekerkhove, Alexander W. Wyatt, Werner J. Struss et al.|European Urology|2019Cited by 183
Evolution of Castration-Resistant Prostate Cancer in ctDNA during Sequential Androgen Receptor Pathway InhibitionMatti Annala, Alexander W. Wyatt, Sinja Taavitsainen et al.|Clinical Cancer Research|2021Cited by 94
<i>BRCA2</i> , <i>ATM</i> , and <i>CDK12</i> Defects Differentially Shape Prostate Tumor Driver Genomics and Clinical AggressionEvan W. Warner, Alexander W. Wyatt, Cameron Herberts et al.|Clinical Cancer Research|2021Cited by 87